Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)

PHASE4CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Infliximab

"Prior to week 26~* Infliximab 3mg/kg standard regime (weeks 0, 2, 6, 14, 22)~* Methotrexate commencing at 10mg weekly, progressing to 20mg by week 6.~* Folic acid 5 mg daily except the day methotrexate is taken~Patients will be unblinded at week 26 and then treated pragmatically guided by disease activity"

DRUG

Methylprednisolone

Steroid

DRUG

Methotrexate

All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.

DIETARY_SUPPLEMENT

Folic acid

All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.

Trial Locations (1)

LS7 4SA

Chapel Allerton Hospital, Leeds

All Listed Sponsors
lead

University of Leeds

OTHER

NCT01308255 - Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA) | Biotech Hunter | Biotech Hunter